mt1002
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 29, 2019 (NCT04116840)
Timeline
Indications
Mechanism of action
Integrin alpha-V/beta-3/alpha-V/beta-5 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06533358 | Phase 2 | Feb 27, 2024 | Shaanxi Micot Technology Limited Company |
| NCT05323136 | Phase 1 | Apr 15, 2022 | Shaanxi Micot Technology Limited Company |
| NCT04723186 | Phase 2 | Dec 2, 2020 | Shaanxi Micot Technology Limited Company |
| NCT04116840 | Phase 1 | Apr 29, 2019 | Pharmaron, Shaanxi Micot Technology Limited Company |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shaanxi Micot Technology Limited Company | For profit | 4 | 4 | 2 | 2019 |
| Pharmaron | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1